● neutral
Impact
PhaseApproved (IBS-C and hyperphosphatemia); Phase 3 for CIC
Time to marketAlready on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
tenapanor Updated Nov 5
What to watch
Tenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.
Bull case
- IBSRELA revenue grew 23% YoY to $96.3M in Q3 2026, with full-year guidance of $350-370M, showing strong commercial execution in a $4.5B+ IBS-C market
- Analyst consensus is heavily bullish: 16 of 17 analysts rate Buy or Strong Buy, with a mean price target of $12.80 (289% upside from $3.29)
- New USPTO patent covering commercial formulations extends IP protection to December 2041, providing long-term exclusivity
Bear case
- Revenue growth is decelerating: from 58% YoY in Q1 2026 to 33% in Q2 to 23% in Q3, and XPHOZAH growth slowed to just 7% in Q3
- Multiple insiders sold shares on August 21, 2026 at ~$3.86, including the CEO (Michael Raab sold ~$168K), CFO, and other officers, which may signal limited near-term upside conviction
- Several prominent hedge funds exited or severely trimmed positions in Q2 2026: Point72 exited entirely, Citadel trimmed 70%, Marshall Wace cut 96.5%, and D.E. Shaw cut 95.8%